Cathie Wood’s ARK Invest Sells 3.6 Million Shares of Syros Pharma

One ARK Invest exchange-traded fund run by ETF star Cathie Wood sold nearly 3.6 million shares of Syros Pharmaceuticals Inc. (NASDAQ: SYRS) on Wednesday, as the share price of this fund traded up nearly 2% in the day’s session. The fund’s share price has greatly improved over the past year.

ARK Innovation ETF (NYSEARCA: ARKK) sold 3,574,908 shares of Syros Pharma. At Wednesday’s closing price, this would have valued this sale at roughly $20.0 million. This is only a small fraction of the total holdings. ARKK is up 81% over the past 52 weeks.

Here is a quick look at all the other sales that took place across all ARK ETFs:

FundTickerCompanyShares
ARKF6060HKZHONGAN ONLINE P&C INSURANCE CO LTD677,300
ARKFGWREGUIDEWIRE SOFTWARE INC246
ARKGGHGUARDANT HEALTH INC10,800
ARKGNVSNOVARTIS AG166,980
ARKGPSTIPLURISTEM THERAPEUTICS INC50,671
ARKGTAKTAKEDA PHARMACEUTICAL CO LTD78,202
ARKKSYRSSYROS PHARMACEUTICALS INC3,574,908
ARKKONVOORGANOVO HOLDINGS INC8,989
ARKKHUYAHUYA INC486,140
ARKQAVAVAEROVIRONMENT INC11,207
ARKQGLEOGALILEO ACQUISITION CORP22,423
ARKQADSKAUTODESK INC119
ARKXRAVNRAVEN INDUSTRIES INC9,215
ARKXADSKAUTODESK INC23
ARKXWKHSWORKHORSE GROUP INC6

Catherine Wood, the CEO and CIO of ARK Investment Management, is a minority and nonvoting shareholder of 24/7 Wall St., owner of 247wallst.com.

Source: Read Full Article